We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With GE HealthCare (GEHC) Q1 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that GE HealthCare Technologies (GEHC - Free Report) will announce quarterly earnings of $0.91 per share in its forthcoming report, representing an increase of 1.1% year over year. Revenues are projected to reach $4.66 billion, increasing 0.2% from the same quarter last year.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some GE HealthCare metrics that are commonly tracked and projected by analysts on Wall Street.
According to the collective judgment of analysts, 'Revenues- Imaging' should come in at $2.03 billion. The estimate indicates a year-over-year change of -17.8%.
Based on the collective assessment of analysts, 'Revenues- Ultrasound' should arrive at $1.22 billion. The estimate suggests a change of +48.5% year over year.
The combined assessment of analysts suggests that 'Revenues- Other' will likely reach $13.30 million. The estimate points to a change of -11.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- PDx' of $631.52 million. The estimate indicates a year-over-year change of +5.4%.
Analysts forecast 'Revenues- PCS' to reach $749.38 million. The estimate indicates a year-over-year change of +0.3%.
Shares of GE HealthCare have experienced a change of -14.5% in the past month compared to the -4.3% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), GEHC is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With GE HealthCare (GEHC) Q1 Earnings: Wall Street's Insights on Key Metrics
Analysts on Wall Street project that GE HealthCare Technologies (GEHC - Free Report) will announce quarterly earnings of $0.91 per share in its forthcoming report, representing an increase of 1.1% year over year. Revenues are projected to reach $4.66 billion, increasing 0.2% from the same quarter last year.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some GE HealthCare metrics that are commonly tracked and projected by analysts on Wall Street.
According to the collective judgment of analysts, 'Revenues- Imaging' should come in at $2.03 billion. The estimate indicates a year-over-year change of -17.8%.
Based on the collective assessment of analysts, 'Revenues- Ultrasound' should arrive at $1.22 billion. The estimate suggests a change of +48.5% year over year.
The combined assessment of analysts suggests that 'Revenues- Other' will likely reach $13.30 million. The estimate points to a change of -11.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- PDx' of $631.52 million. The estimate indicates a year-over-year change of +5.4%.
Analysts forecast 'Revenues- PCS' to reach $749.38 million. The estimate indicates a year-over-year change of +0.3%.
View all Key Company Metrics for GE HealthCare here>>>
Shares of GE HealthCare have experienced a change of -14.5% in the past month compared to the -4.3% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), GEHC is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>